Abstract
BackgroundImmune checkpoint inhibitors (IO) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). In the pre-IO era, patients (pts) with squamous cell carcinoma (SCC) had worse survival outcomes...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have